Hikal Ltd
NSE:HIKAL

Watchlist Manager
Hikal Ltd Logo
Hikal Ltd
NSE:HIKAL
Watchlist
Price: 391.05 INR 1.12% Market Closed
Market Cap: 48.2B INR
Have any thoughts about
Hikal Ltd?
Write Note

Relative Value

The Relative Value of one HIKAL stock under the Base Case scenario is 352.37 INR. Compared to the current market price of 391.05 INR, Hikal Ltd is Overvalued by 10%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

HIKAL Relative Value
Base Case
352.37 INR
Overvaluation 10%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
12
vs Industry
46
Median 3Y
2.1
Median 5Y
1.9
Industry
2.5
Forward
2.4
vs History
1
vs Industry
6
Median 3Y
46.5
Median 5Y
35.9
Industry
21.9
Forward
43.6
vs History
6
vs Industry
20
Median 3Y
17.2
Median 5Y
12.1
Industry
16.5
vs History
vs Industry
2
Median 3Y
105.6
Median 5Y
77.3
Industry
23.6
vs History
22
vs Industry
22
Median 3Y
3.5
Median 5Y
3.2
Industry
2.1
vs History
12
vs Industry
42
Median 3Y
2.3
Median 5Y
2.1
Industry
2.6
Forward
2.6
vs History
22
vs Industry
42
Median 3Y
4.8
Median 5Y
4.3
Industry
5.2
vs History
6
vs Industry
21
Median 3Y
15.7
Median 5Y
14.8
Industry
13.3
Forward
15.7
vs History
3
vs Industry
13
Median 3Y
26.1
Median 5Y
23.2
Industry
16.6
Forward
24.2
vs History
4
vs Industry
18
Median 3Y
18
Median 5Y
13.5
Industry
15.6
vs History
vs Industry
8
Median 3Y
57
Median 5Y
24.6
Industry
19.1
vs History
20
vs Industry
35
Median 3Y
2.1
Median 5Y
2
Industry
1.9

Multiples Across Competitors

HIKAL Competitors Multiples
Hikal Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
IN
Hikal Ltd
NSE:HIKAL
48.2B INR 2.7 71.1 19.3 34.1
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY 4 211 733 -5 347 888.9 -5 459 134.4 -5 046 864.6
US
Eli Lilly and Co
NYSE:LLY
710.5B USD 17.4 84.9 45.7 51
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
DK
Novo Nordisk A/S
CSE:NOVO B
3.3T DKK 12.3 35 24.3 27.8
US
Johnson & Johnson
NYSE:JNJ
373.5B USD 4.3 25.4 12.3 16
US
Merck & Co Inc
NYSE:MRK
251.1B USD 4 20.7 10.5 12.5
CH
Roche Holding AG
SIX:ROG
202.7B CHF 3.5 17.6 9.9 11.8
CH
Novartis AG
SIX:NOVN
183.3B CHF 4.1 11.6 10.1 14
UK
AstraZeneca PLC
LSE:AZN
162.4B GBP 4.1 31.6 169.4 253.9
IE
Endo International PLC
LSE:0Y5F
146B USD 63 -49.9 234.4 587.7
P/E Multiple
Earnings Growth
IN
Hikal Ltd
NSE:HIKAL
Average P/E: 37.3
71.1
N/A
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 347 888.9 N/A
US
Eli Lilly and Co
NYSE:LLY
84.9
451%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A
DK
Novo Nordisk A/S
CSE:NOVO B
35
86%
US
Johnson & Johnson
NYSE:JNJ
25.4
-22%
US
Merck & Co Inc
NYSE:MRK
20.7
7 321%
CH
Roche Holding AG
SIX:ROG
17.6
32%
CH
Novartis AG
SIX:NOVN
11.6
21%
UK
AstraZeneca PLC
LSE:AZN
31.6
177%
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -49.9 N/A

See Also

Discover More
Back to Top